Trombose venosa profunda extensa como complicação de um tumor do testículo tratado com o protocolo BEP (cisplatina, bleomicina e etoposide)
Relato de caso
Palavras-chave:
Trombose venosa, Câncer do testículo, Quimioterapia, Fibrinolíticos, Embolia pulmonarResumo
CONTEXTO: Não há relatos na literatura de trombose venosa profunda (TVP) extensa associada ao protocolo de quimioterapia cisplatina, bleomicina e etoposite (BEP). RELATO DO CASO: O paciente era um adolescente de 18 anos com um tumor germinativo não-seminomatoso no testículo direito, com metástases pulmonares, hepáticas e retroperitoneais. Após orquiectomia radical, o paciente começou a receber quimioterapia de acordo com o protocolo BEP (sem profilaxia rotineira para TVP). No quarto dia do ciclo, TVP massiva foi diagnosticada, estendendo-se das veias poplíteas até o segmento inferior da veia cava torácica. Tratamento trombolítico foi iniciado imediatamente com estreptoquinase. No segundo dia da terapia trombolítica, o paciente desenvolveu insuficiência renal aguda, devido ao acometimento das veias renais pela trombose. Estroptoquinase foi mantida por seis dias e o paciente teve evolução surpreendentemente favorável.
Downloads
Referências
Doll DC, Yarbro JW. Vascular toxicity associated with antineo- plastic agents. Semin Oncol. 1992;19(5):580-96.
Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. Oncologist. 1999;4(6):443-9.
Sugden EM, Griffiths CL, Greywoode GI, Lewis SM. Acute abdomen during adjuvant chemotherapy: superior mesenteric artery thrombosis associated with CMF chemotherapy. Clin Oncol (R Coll Radiol). 2001;13(6):441-3.
Lepidini G, Biancari F, D’Andrea V. Severe thrombosis after chemotherapy for metastatic choriocarcinoma of the testis maintaining complete remission for a long period. Scand J Urol Nephrol. 1997;31(2):221-2.
Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72(2):587-93.
Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13-14):2229-38.
Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6 Pt 1):2021-4.
Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs. 1994;5(6):607-14.
Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552-6.
Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemo- therapy. Cancer Chemother Pharmacol. 1987;19(3):253-6.
Cantwell BM, Mannix KA, Roberts JT, Ghani SE, Harris AL. Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet. 1988;2(8619):1086-7.
Hall MR, Richards MA, Harper PG. Thromboembolic events during combination chemotherapy for germ cell malignancy. Lancet. 1988;2(8622):1259.
Lederman GS, Garnick MB. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol. 1987;137(6):1236-7.
Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986;4(9):1405-17.
Stockler M, Raghavan D. Neoplastic venous involvement and pulmonary embolism in patients with germ cell tumors. Cancer. 1991;68(12):2633-6.
Oberhoff C, Winkler UH, Tauchert AM, Schindler AE. Adjuvante CMF-Chemotherapie bei Patientinnen mit Mammakarzinom--Auswirkungen auf Blutgerinnung und Fibrinolyse. [Adjuvant CMF chemotherapy in patients with breast cancer--results on blood coagulation and fibrinolysis]. Zentralbl Gynakol. 1997;119(5):211-7.
Taher A, Shamsseddine A, Saghir N, et al. Acquired protein C deficiency following cisplatinum-navelbine administration for locally advanced breast cancer. Case report. Eur J Gynaecol Oncol. 1999;20(4)323-4.
Vos AH, Splinter TA, van der Heul C. Arterial occlusive events during chemotherapy for germ cell cancer. Neth J Med. 2001;59(6):295-9.
Bachmeyer C, Joly H, Jorest R. Early myocardial infarction during chemotherapy for testicular cancer. Tumori. 2000;86(5):428-30.
Schmidt J, Zenut M, De Marquilly F, Maciejewski C, Plagne R, Lavarenne J. Thrombose artérielle chez un patient traité par chimio- thérapie (Protocole BEP) pour un dysgerminome extra-gonadique. [Arterial thrombosis in a patient after chemotherapy (BEP protocol) for extra-gonadal dysgerminoma]. Therapie. 1995;50(5):476-8.
Yamada K, Yamashiro S, Itoyama Y, Goto S, Uemura S, Ushio Y. [Sinus thrombosis during CDDP and VP-16 (PE) therapy for suprasellar germ-cell tumor: case report]. No Shinkei Geka. 1993;21(11):1025-9.
Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemo- therapy for non-seminomatous testicular cancer. Ann Oncol. 2002;13(2):229-36.
Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18(10):2169-78.
Shlebak AA, Smith DB. Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemother Pharmacol. 1997;39(5):462-6.
Dhami MS, Bona RD. Thrombosis in patients with cancer. Postgrad Med. 1993;93(8):131-3, 137-40.
Marder VJ. Thrombolytic therapy: overview of results in major vascular occlusions. Thromb Haemost. 1995;74(1):101-5.
Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin- based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48-51.
Orlando L, Colleoni M, Nole F, et al. Incidence of venous thromboembolism in breast cancer patients during chemo- therapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? Ann Oncol. 2000;11(1):117-8.
Ng CM, Rivera JO. Meta-analysis of streptokinase and heparin in deep vein thrombosis. Am J Health Syst Pharm. 1998;55(19):1995-2001.
Gallus AS. Thrombolytic therapy for venous thrombosis and pulmonary embolism. Baillieres Clin Haematol. 1998;11(3):663-73.
Albuquerque LC, Silveira F, Zago AJ, Bettio J, Petracco JB. Terapia trombolítica em trombose venosa profunda. Experi- ência clínica inicial. [Thrombolytic therapy in deep venous thrombosis. Initial clinical experience]. Arq Bras Cardiol. 1997;68(2):125-8.
Weidmann B, Jansen W, Franzen B, Tauchert M. Lysetherapie bei tiefen Beinvenenthrombosen. [Fibrinolytic therapy of deep vein thombosis]. Med Klin (Munich). 1999;94(3):140-9.
Rühlmann C, Engelmann L, Scheel H, Siegemund A, Biesold M. Thrombolyse einer ausgedehnten Venenthrombose der unteren Körperhälfte bei Anomalie der Vena cava inferior. [Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior]. Dtsch Med Wochenschr. 1996;121(5):124-8.
Comerota AJ, Katz ML, White JV. Thrombolytic therapy for acute deep venous thrombosis: how much is enough? Cardiovasc Surg. 1996;4(1):101-4.
Sillesen H, Just S, Jorgensen M, Baekgaard N. Catheter di- rected thrombolysis for treatment of ilio-femoral deep venous thrombosis is durable, preserves venous valve function and may prevent chronic venous insufficiency. Eur J Vasc Endovasc Surg. 2005;30(5):556-62.
Chiou AC, Biggs KL, Matsumura JS. Vena cava filters: why, when, what, how? Perspect Vasc Surg Endovasc Ther. 2005;17(4):329-39.
Koga F, Yamada T, Ishimaru H, Sadaoka SI, Mizuo T. Deep vein thrombosis during chemotherapy in a patient with advanced testicular cancer: successful percutaneous thrombectomy under temporary placement of retrievable inferior vena cava filter. Int J Urol. 2001;8(2):90-3.
Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Throm- bolytic Therapy. Chest. 2004;126(3 Suppl):401S-428S.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
